Macleods Pharmaceuticals Ltd.

Macleods Pharmaceuticals Ltd. (also styled Macleods Pharmaceuticals Limited; US affiliate Macleods Pharma USA, Inc.) is an Indian generic-drug manufacturer headquartered in Mumbai, Maharashtra. It was founded in 1986 by the Bawri/Agarwal brothers and formally incorporated on 5 June 1989 (CIN U24239MH1989PLC052049). It is privately held — an unlisted Indian public limited company controlled by the founding family — and has no ticker; it filed a draft red herring prospectus in 2022 but put a planned IPO on hold. Headcount estimates vary widely by source (roughly 12,000–23,000), and reported standalone revenue runs about ₹9,000 crore (~$1.1B) for FY2025, though these figures are from third-party databases and not audited public filings.

Operations. Macleods develops and manufactures finished-dosage generics plus active pharmaceutical ingredients, operating multiple Indian plants (including Daman, Baddi, Sikkim and Indore) with US FDA, UK MHRA and WHO-GMP approvals. Product lines span tablets, capsules, liquid orals, suspensions, injectables, pressurized metered-dose and dry-powder inhalers, and topicals. Therapeutic focus areas include anti-tuberculosis drugs, anti-infectives/antibiotics, cardiovascular, anti-diabetic, antiretrovirals/HIV, antimalarials, dermatology and hormones. It is a major supplier of WHO-prequalified TB, HIV and malaria medicines, and its US arm had filed roughly 185 ANDAs (about 100 approved) as of August 2023.

Litigation posture. Macleods is an operating company defending against brand-pharma patent suits — 1 tracked case, 0 as plaintiff. The single tracked matter is Merck Sharp & Dohme Corp. v. Macleods Pharmaceuticals Ltd. et al., No. 1:19-cv-00316 (D. Del.), a Hatch-Waxman ANDA action filed 13 February 2019 asserting U.S. Patent 7,326,708 and later folded into MDL 19-md-2902; it ended in a consent judgment in April 2020. Venue was the District of Delaware, the standard forum for ANDA litigation.

Context. Public dockets indicate Macleods has been sued repeatedly in similar Paragraph IV/ANDA disputes by other brand owners (e.g., Gilead, Bayer, Otsuka, ZS Pharma, Anacor), but only the Merck case is captured in our data. This is generic-drug patent defense work, not NPE assertion.